×
X logo

Today's breaking news and more in your inbox.

I'm interested in (please check all that apply)

You may opt-out anytime by clicking "unsubscribe" from the newsletter or from your account.

Don’t End Medical Innovation

Editor, News-Register:

When I read that President Biden was considering enacting Medicare negotiation to reduce inflation, I was very upset. While the president has argued that this measure will lower prescription costs and decrease inflation, the reality is more complicated. This measure could have major impacts on pharmaceutical innovation, significantly reducing research and development and limiting the number of new cures and treatments available for patients. For me, this issue is incredibly personal.

No one ever expects to get sick, and I was no exception. Shortly after graduating college in 2014, I was starting a new job as an ER nurse when it was discovered that I was in end stage renal failure. After two years of working in the ER while on at-home peritoneal dialysis, the buildup of fluids in my body caused congestive heart failure and a heart attack. It was so bad that I had to go on in-center hemodialysis. I truly didn’t know if I was going to survive the whole ordeal.

Luckily after a total of six years on dialysis, I was eventually able to receive a kidney transplant in April of 2021. These days, life is much more normal. However, I still heavily rely on many different medications to keep me and my donor kidney healthy.

That’s why we can’t afford to stop pharmaceutical innovation in its tracks. Without such medical investigation and exploration, I may not have fared as well as I have. I am living proof that illness happens when you least expect it. We need to make certain that research and development can continue, so all patients can get the treatments they need.

Danielle L. Campbell, RN, BSN

End Stage Renal Disease/Transplant Patient

Wheeling

NEWSLETTER

Today's breaking news and more in your inbox

I'm interested in (please check all that apply)
Are you a paying subscriber to the newspaper? *

COMMENTS

Starting at $4.73/week.

Subscribe Today